Safety and Efficacy Study of Enzalutamide

[1] Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer (PROSPER) | NCT02003924
[2] American Cancer Society. Global Facts & Figures. https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/global-cancer-facts-and-figures/global-cancer-facts-and-figures-3rd-edition.pdf. Accessed January 10, 2018.
[3] American Cancer Society. Cancer Facts & Figures 2018. https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2018/cancer-facts-and-figures-2018.pdf. Accessed January 10, 2018.
[4] European Commission. Epidemiology of Prostate Cancer in Europe. https://ec.europa.eu/jrc/en/publication/epidemiology-prostate-cancer-europe. Accessed January 10, 2018.
[5] Urology Care Foundation. Advanced Prostate Cancer Patient Guide. www.urologyhealth.org/educational-materials. Accessed February 16, 2017.
[6] Luo J, Beer T, Graff J. Treatment of Non-metastatic Castration Resistant Prostate Cancer. Oncology. April 2016, 30(4):336-344.
[7] Smith MR, Kabbinavar F, Saad F, Hussain A et al. Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer. J Clin Oncol 2005; 23: 2918?2925.
[8] A Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) (ARCHES) | NCT02677896
[9] Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK) | NCT02319837.